{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:15:12Z","timestamp":1770070512126,"version":"3.49.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"24","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>A case of osteomyelitis caused by multidrug-resistant (MDR) Pseudomonas aeruginosa is reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>An 84-year-old Caucasian male with an underlying history of type 2 diabetes, peripheral vascular disease, and coronary artery disease had chronic nonhealing wounds on his right foot. Wound care and a course of intravenous (IV) ertapenem with oral ciprofloxacin were ineffective. His initial wound culture grew Staphylococcus aureus, group G streptococcus and P. aeruginosa; the Pseudomonas was susceptible to multiple agents. The patient eventually required midtarsal amputation and angioplasties to his right leg. Twenty days after the operation, 2 openings were discovered at the surgical site, 1 of which was probed to the bone. He was readmitted 5 weeks after the operation. A repeat wound swab grew MDR P. aeruginosa and Finegoldia magna. The Pseudomonas was susceptible to gentamicin and colistin. The patient had revision of the infected amputation site with the goal of salvaging his right lower limb. The patient developed acute renal failure after 26 days of IV gentamicin, IV ceftriaxone, and oral metronidazole. Additional susceptibility testing was performed to identify alternatives. The bacteria were considered susceptible to IV fosfomycin, the last resort, by our microbiology laboratory. This was combined with ceftolozane\/tazobactam followed by meropenem to treat the residual infection. After 2 weeks of IV fosfomycin, the patient\u2019s wound improved and further amputation was avoided.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our case demonstrates that IV fosfomycin may provide an effective salvage therapy when combined with \u03b2-lactams for the treatment of severe diabetic foot infection or osteomyelitis caused by MDR P. aeruginosa.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxab294","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T15:42:16Z","timestamp":1627314136000},"page":"2209-2215","source":"Crossref","is-referenced-by-count":14,"title":["Intravenous fosfomycin as salvage therapy for osteomyelitis caused by multidrug-resistant <i>Pseudomonas aeruginosa<\/i>"],"prefix":"10.1093","volume":"78","author":[{"given":"Maggie","family":"Wong","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Royal Columbian Hospital, Fraser Health Authority, New Westminster, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davie","family":"Wong","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of British Columbia, Vancouver, British Columbia, and Department of Medicine, Royal Columbian Hospital, Fraser Health Authority, New Westminster, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangita","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of British Columbia, Vancouver, British Columbia, and Royal Columbian Hospital, New Westminster, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"issue":"4","key":"2021121005422388800_CIT0001","doi-asserted-by":"crossref","first-page":"e00031","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"2021121005422388800_CIT0002","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/jac\/dkz285","article-title":"Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007\u201316 study","volume":"74","author":"McCracken","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2021121005422388800_CIT0003","author":"World Health Organization","year":"2017"},{"key":"2021121005422388800_CIT0004","author":"Tamma","year":"2020"},{"issue":"8","key":"2021121005422388800_CIT0005","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/antibiotics9080500","article-title":"Fosfomycin as partner drug for systemic infection management. a systematic review of its synergistic properties from in vitro and in vivo studies","volume":"9","author":"Antonello","year":"2020","journal-title":"Antibiotics"},{"issue":"7","key":"2021121005422388800_CIT0006","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/527442","article-title":"Fosfomycin: use beyond urinary tract and gastrointestinal infections","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021121005422388800_CIT0007","first-page":"30","article-title":"The role of fosfomycin in osteoarticular infection","volume":"32","author":"Morata","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"2021121005422388800_CIT0008","author":"Ivozfo (fosfomycin for injection)"},{"key":"2021121005422388800_CIT0009","doi-asserted-by":"crossref","first-page":"8912039","DOI":"10.1155\/2018\/8912039","article-title":"Intravenous fosfomycin: an assessment of its potential for use in the treatment of systemic infections in Canada","volume":"2018","author":"Zhanel","year":"2018","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"7","key":"2021121005422388800_CIT0010","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jac\/dkaa095","article-title":"In vitro synergy of ceftolozane\/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa","volume":"75","author":"Cuba","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"2021121005422388800_CIT0011","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/phar.1434","article-title":"Fosfomycin for the treatment of resistant gram-negative bacterial infections","volume":"34","author":"Reffert","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"6","key":"2021121005422388800_CIT0012","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/QCO.0000000000000597","article-title":"The role of fosfomycin for multidrug-resistant gram-negative infections","volume":"32","author":"Bassetti","year":"2019","journal-title":"Curr Opin Infect Dis"},{"issue":"6","key":"2021121005422388800_CIT0013","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1099\/jmm.0.000984","article-title":"Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa","volume":"68","author":"Avery","year":"2019","journal-title":"J Med Microbiol"},{"key":"2021121005422388800_CIT0014","first-page":"45","article-title":"Fosfomycin in infections caused by multidrug-resistant gram-negative pathogens","volume":"32","author":"Ramos","year":"2019","journal-title":"Rev Esp Quimioter"},{"issue":"3","key":"2021121005422388800_CIT0015","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/00365548.2011.616221","article-title":"Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria","volume":"44","author":"Dinh","year":"2012","journal-title":"Scand J Infect Dis"},{"issue":"5","key":"2021121005422388800_CIT0016","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s15010-019-01323-4","article-title":"Current clinical use of intravenous fosfomycin in ICU patients in two European countries","volume":"47","author":"Putensen","year":"2019","journal-title":"Infection"},{"issue":"5","key":"2021121005422388800_CIT0017","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1179\/joc.2005.17.5.527","article-title":"Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin","volume":"17","author":"Stengel","year":"2005","journal-title":"J Chemother"},{"issue":"3","key":"2021121005422388800_CIT0018","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/jac\/dkp230","article-title":"High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection","volume":"64","author":"Schintler","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2021121005422388800_CIT0019","doi-asserted-by":"crossref","first-page":"ofaa572","DOI":"10.1093\/ofid\/ofaa572","article-title":"Cure of limb-threatening XDR Pseudomonas aeruginosa infection: combining genome sequencing, therapeutic drug level monitoring, and surgical debridement","volume":"8","author":"Narayanasamy","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"2021121005422388800_CIT0020","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/BF01644014","article-title":"Adjuvant fosfomycin medication in chronic osteomyelitis","volume":"17","author":"Meissner","year":"1989","journal-title":"Infection"},{"issue":"7","key":"2021121005422388800_CIT0021","doi-asserted-by":"crossref","first-page":"e0201667","DOI":"10.1371\/journal.pone.0201667","article-title":"Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis","volume":"13","author":"Yu","year":"2018","journal-title":"PLOS ONE"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxab294\/39620621\/zxab294.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/24\/2209\/41710263\/zxab294.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/24\/2209\/41710263\/zxab294.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T05:45:47Z","timestamp":1639115147000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/78\/24\/2209\/6328602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":21,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2021,7,26]]},"published-print":{"date-parts":[[2021,12,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxab294","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,15]]},"published":{"date-parts":[[2021,7,26]]}}}